Nanjing Well Pharmaceutical Group Co.,Ltd.
603351.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.86B
Close$
$81.35
205.7% upside
Current Fair Value
205.7% upsideUndervalued by 205.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.86 Billion |
|---|---|
| Enterprise Value | $4.08 Billion |
| Dividend Yield | $0.60 (2.11%) |
| Earnings per Share | $1.11 |
| Beta | 0.13 |
| Outstanding Shares | 135,439,132 |
Return
| Return on Equity | 8.67% |
|---|---|
| Return on Assets | 6.33% |
| Return on Invested Capital | 10.06% |
Valuation & Multiples
| P/E Ratio | 24.98 |
|---|---|
| PEG | 304.37 |
| Price to Sales | 2.66 |
| Price to Book Ratio | 2.05 |
| Enterprise Value to Revenue | 2.91 |
| Enterprise Value to EBIT | 21.92 |
| Enterprise Value to Net Income | 26 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.24 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Nanjing Well Pharmaceutical Group Co.,Ltd.
718 employees
CEO: Renrong Wu Nanjing Well Pharmaceutical Group Co., Ltd., founded in 2000 and headquartered in Nanjing, China, is primarily engaged in the research, development, manufacturing, and distribution of pharmaceutical excipients within the Chinese market. ...